Market Risers: Centralnic Group, GlaxoSmithKline, GSTechnologies Ltd, Imperial Brands

Broker Ratings

The trading price for Centralnic Group ticker lookup code: LON:CNIC has risen 6.47% or 5.5 points throughout today’s trading session so far. Buyers seem confident during the session. The period high was 90.5 and a low of 85.55. The total volume of shares exchanged through this period comes to 61,974 while the daily average number of shares exchanged is 202,841. A 52 week high for the stock is 99.5 around 14.5 points different to the previous business close and a 52 week low sitting at 57 which is a variance of 28 points. Centralnic Group has a 20 day moving average of 88.27 and now the 50 day moving average at 85.53. The market capitalisation is now £211.53m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for Centralnic Group being recorded at Monday, December 7, 2020 at 11:52:55 AM GMT with the stock price trading at 90.5 GBX.

The stock price for GlaxoSmithKline ticker code: LON:GSK has stepped up 2.07% or 28.75 points during today’s session so far. Market buyers have so far held a positive outlook during the session. Range high for the period has seen 1418.6 dropping as low as 1391.4. The volume total for shares traded up to this point was 2,087,896 with the daily average at 11,923,308. The 52 week high is 1857 which comes in at 471 points in difference on the previous days close and a 52 week low being 1284 making a difference of 102 points. GlaxoSmithKline now has a 20 moving average of 1421.11 and also a 50 day SMA of 1416.39. This puts the market cap at £70,984.10m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for GlaxoSmithKline being recorded at Monday, December 7, 2020 at 12:29:57 PM GMT with the stock price trading at 1414.75 GBX.

The trading price for GSTechnologies Ltd ticker code: LON:GST has stepped up 5.38% or 0.01 points throughout today’s trading session so far. Market buyers are a positive bunch throughout the session. The periods high figure was 0.14 meanwhile the session low reached 0.12. The total volume of shares traded by this point was 710,599 with the average number of shares traded daily being 2,481,904. The stock 52 week high is 0.27 which is 0.14 points difference from the previous days close and the 52 week low at 0.11 is a variance of 0.02 points. GSTechnologies Ltd now has a 20 simple moving average of 0.17 and also a 50 day moving average of 0.21. The current market capitalisation is £1.36m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for GSTechnologies Ltd being recorded at Monday, December 7, 2020 at 11:00:23 AM GMT with the stock price trading at 0.14 GBX.

The trading price for Imperial Brands found using EPIC: LON:IMB has risen 2.72% or 39.84 points throughout today’s trading session so far. Market buyers have remained positive during this period. The periods high has already touched 1512.12 dropping as low as 1460.5. The total volume of shares traded by this point was 845,610 while the daily average number of shares exchanged is 2,870,592. The 52 week high is 2072 which comes in at 605 points difference from the previous days close and the 52 week low at 1203 making a difference of 264 points. Imperial Brands now has a 20 moving average of 1439.49 and a 50 day moving average at 1371.58. The current market capitalisation is £14,260.83m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for Imperial Brands being recorded at Monday, December 7, 2020 at 12:29:45 PM GMT with the stock price trading at 1506.84 GBX.

Share on:
Find more news, interviews, share price & company profile here for:
GSK announces the EMA's review of Nucala (mepolizumab) as a potential add-on treatment for COPD, promising hope for 40 million patients battling this condition.
GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor.
GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates.
GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns.
GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results.
GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe.

Search

Search